Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
Executive Summary
The promise of health care savings from an abundance of biosimilar drugs brought to market under recently passed reforms may go unfulfilled if intellectual property provisions of the law aren't addressed, members of a panel at the BIO annual meeting in Chicago said May 5
You may also be interested in...
CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal
While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.
FDA Antibiotic Task Force Developing Standards To Help Products GAIN Traction
Task force model emerging as agency’s standard approach to implementing statutory directives to enhance product development.
PDUFA Cost Offset In House Focuses On FDA Petition Review, Not REMS
Faced with a CBO estimate that H.R. 5651 will increase federal spending in fiscal years 2013 through 2022, the House Energy and Commerce Committee applies a section that speeds FDA decisions on some petitions to biosimilars. This contrasts with the Senate bill, which allows FDA to require brand companies to sell products covered by limited distribution systems to generic firms.